The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (8.45) USD. With the latest stock price at 0.69 USD, the upside of Nektar Therapeutics based on DCF is -1333.7%.
Based on the latest price of 0.69 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 1333.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.0% - 7.8% | 6.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (23.06) - (5.28) | (8.45) |
| Upside | -3466.6% - -871.2% | -1333.7% |